

Product Information and Testing - Amended

Product Information

Product Name	WA19
Lot Number	WB0039
Parent Material	WA19-WB0013
Depositor	WiCell
Banked by	WiCell
Thaw Recommendation	Thaw 1 vial into 4 wells of a 6 well plate.
Culture Platform	Feeder Independent
	Medium: mTeSR1
	Matrix: Matrigel
Protocol	WiCell Feeder Independent Protocol
Passage Number	p9
	These cells were cultured for 8 passages prior to freeze. WiCell adds +1 to the passage number at freeze so that the number on the vial best represents the overall passage number of the cells at thaw.
Date Vialed	27-July-2010
Vial Label	WB0039 WA19 P9 LK 27JUL10
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.

Lot Specific Testing Performed by WiCell The following tests were performed on this specific lot.

Test Description	Test Provider	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	 ≥ 15 Undifferentiated Colonies, ≤ 30% Differentiation 	Pass
Identity by STR	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega	Consistent with known profile	Pass
Sterility - Direct transfer method	Apptec	30744	Negative	Pass
Mycoplasma	Bionique	M250	No contamination detected	Pass
Karyotype by G-banding	WiCell	SOP-CH-003	Normal karyotype	Pass



Product Information and Testing - Amended

General Cell Line Testing Performed by WiCell The following tests were performed on the cell line. The tests do not apply to any particular lot.

Test Description	Test Provider	Test Method
Differentiation Potential by	WiCell	SOP-CH-213
Teratoma		SOP-CH-214
HLA	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega
ABO	American Red Cross	For ABO: Olsson ML, Chester MA. A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 1995; 69(3):242-7. For RHD: Singleton BK, Green CA, Avent ND, Martin PG, Smart E, Daka A, Narter-Olaga EG, Hawthorne LM, Daniels G. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000; 95(1): 12-8.
Growth Curve (Doubling Time)	WiCell	Varies by culture platform
Flow Cytometry for ESC Marker	UW Flow Cytometry	SOP-CH-101
Expression	Laboratory	SOP-CH-102
		SOP-CH-103
		SOP-CH-105
Array Comparative Genomic	WiCell	SOP-CH-308
Hybridization (aCGH)		SOP-CH-309
		SOP-CH-310
Comprehensive Human Virus Panel	Charles River	ID 91/0

Date of Lot Release	Quality Assurance Approval
18-March-2011	8/6/2015 AMK Quality Assurance Signed by

©2013 WiCell Research Institute The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.



Histocompatibility/Molecular Diagnostics Laboratory

University of Wisconsin Hospital and Clinics

Short Tandem Repeat Analysis*

Sample Report: 8841-STR

UW HLA#: 63629

Sample Date: 08/20/10 Received Date: 08/20/10

Requestor: WiCell Research Institute Test Date: 08/24/10

File Name: 100824

Report Date: 08/31/10

Sample Name: (label on tube) 8841-STR

Description: DNA Extracted by WiCell 225.94 ng/ μ L; 260/280 = 1.94

Locus	Repeat #	STR Genotype
D16S539	5,8-15	13,13
D7S820	6-14	9,10
D13S317	7-15	12,12
D5S818	7-15	11,11
CSF1PO	6-15	11,13
TPOX	6-13	8,11
Amelogenin	NA	X,Y
TH01	5-11	7,7
vWA	11, 13-21	16,18

Comments: Based on the 8841-STR DNA dated and received on 08/20/10 from WI Cell, this sample (UW HLA# 63629) exactly matches the STR profile of the human stem cell line WA19 comprising 12 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human WA19 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 8841-STR DNA sample submitted corresponds to the WA19 stem cell line and was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.

9-7-13

Ager Date HLA/Molecular Diagnostics Laboratory

|01 |10 _____


HLA/Molecular Diagnostics Laboratory

* Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.


Test Facility:

This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.






TEST PARAMETERS	PRODUCT				
Approximate Volume Tested	0.5 mL	0.5 mL 6 FTM 400 mL			
Number Tested	6				
Type of Media	SCD				
Media Volume	400 mL				
Incubation Period	14 Days	14 Days			
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C			
RESULTS	6 NEGATIVE	6 NEGATIVE			



)9-21-10 Date

Testing conducted in accordance with current Good Manufacturing Practices.





This testing procedure was performed in compliance with the FDA's Current Good Manufacturing Practice (cGMP) standards (to the extent that the regulations pertain to the procedures performed) as specified in the Code of Federal Regulations, Title 21 Parts 210 and 211 [21 CFR 210 & 211]. All related records derived from the test procedures have been reviewed by the Quality Assurance Department. The individual's signature below verifies that the methods and procedures referenced above have been followed and that the Final Report accurately reflects the raw data generated during the course of the procedures. All records, including raw data and final reports are archived on site for a minimum of seven years.

The specified test's procedures determine the intervals at which samples are inspected. The medium used for testing must pass quality control mycoplasmal growth promotion testing and sterility testing. Traceability of all of the components used is assured and supporting documentation can be supplied upon request.

Quality Assurance Review Da	ate: 98	10		8 ° 0
Reviewed By	, QA Assista		U	1

NOTE:

- 1. Prior to receipt at Bionique[®] Testing Laboratories, Inc., the stability of the test article is the responsibility of the company submitting the sample. Bionique Testing Laboratories Inc. will assume responsibility for sample stability following receipt and prior to being placed on test.
- 2. This test is for the detection of microbiological growth and does not require statistical validation.

BIONIQUE[®] TESTING LABORATORIES, INC.

APPENDIX

Document ID#:DCF9002FTitle:QUALITY ASSURANCE REPORT - GMPEffective Date:03/12/10Edition #:01

REFERENCES

Regulatory:

- 1. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. FDA. Office of the Federal Register, National Archives and Records Department.
- 2. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. FDA. Office of the Federal Register, National Archives and Records Department.
- Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals, Director, Center for Biologics Evaluation and Research, FDA. May, 1993. Docket No. 84N-0154.
- 4. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 610.30, General Biological Products Standards; Subpart D, Test for Mycoplasma. FDA. Office of the Federal Register, National Archives and Records Department.

General:

- 1. Barile MF, Kern J. Isolation of Mycoplasma arginini from commercial bovine sera and its implication in contaminated cell cultures. Proceedings of the Society for Experimental Biology and Medicine, Volume 138, Number 2, November 1971.
- 2. Chen, T.R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Experimental Cell Research, 104: 255-262, 1977.
- 3. Carolyn K. Lincoln and Daniel J. Lundin. Mycoplasma Detection and Control. U. S. Fed. for Culture Collections Newsletter, Vol. 20, Number 4, 1990.
- 4. Fetal Bovine Serum; Proposed Guideline. National Committee For Clinical Laboratory Standards (NCCLS), Vol. 10, Number 6, 1990. (NCCLS publication M25-P).
- 5. McGarrity GJ, Sarama J, Vanaman V. Cell Culture Techniques. ASM News, Vol. 51, No. 4, 1985.
- 6. Tully JG, Razin S. Methods in Mycoplasmology, Volumes I and II. Academic Press, N.Y., 1983.
- 7. Barile MF, Razin S, Tully JG, Whitcomb RF. The Mycoplasmas, Volumes 1-4. Academic Press, N.Y., 1979.
- 8. <u>http://www.bionique.com/</u> Safe Cells Insights



MYCOPLASMA TESTING SERVICES

APPENDIX IV

Document#:	DCF3013D
Edition#:	10
Effective Date:	07/15/2003
Title:	M-250 FINAL REPORT SHEET

M-250 FINAL REPORT

Direct Specimen Culture Procedure 3008, 3011, 3013

TO: WiCell QA WiCell Research Institute

BTL SAMPLE ID#: 62093	P.O.#	DATE REC'D:	08/10/2010
TEST/CONTROL ARTICLE:			

WA19-WB0039 #8841

LOT#: NA

	the second s		and the second se	
DIRECT CULTURE SET-UP (DAY 0)	DF	ATE:	08/11/201	0
INDICATOR CELL LINE (VERO)	SEE DNA FLUO	ROCHRO	ME RECORD SHEET	_
				DATE
THIOGLYCOLLATE BROTH	DAY 7	+	Θ	08/18/2010
	DAY 28	+	\odot	09/08/2010
BROTH-FORTIFIED COMMERCIAL				
0.5 mL SAMPLE	DAY 7	+	\mathfrak{S}	08/18/2010
6.0 mL BROTH	DAY 28	+	\odot	09/08/2010
BROTH-MODIFIED HAYFLICK				
0.5 ml SAMPLE	DAY 7	+	\odot	08/18/2010
6.0 mL BROTH	DAY 28	+	Θ	09/08/2010
BROTH-HEART INFUSION				
<u>0.5</u> mL SAMPLE	DAY 7	+	Θ	08/18/2010
6.0 mL BROTH	DAY 28	+	Θ	09/08/2010
(See Reverse)				


Page 1 of 2

Document#:	DCF3013	D				
Edition#:	10					
Effective Date:	07/15/2	003				
Title:	M-250 F	INAL REPORT	SHEE	Г		
SAMPLE ID#: 620	93		AER	OBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTIF COMMERCIAL	IED	DAY 7 DAY 14 DAY 21	+ + +	0 0 0	+ (O) + (O) + (O)	08/18/2010 08/25/2010 09/01/2010
AGAR PLATES-MODIFI HAYFLICK	ED	DAY 7 DAY 14 DAY 21	+ + +	000	+ () + () + ()	08/18/2010 08/25/2010 09/01/2010
AGAR PLATES-HEART INFUSION		DAY 7 DAY 14 DAY 21	+ + +	000	+ () + () + ()	08/18/2010 08/25/2010 09/01/2010
BROTH SUBCULTURES	(DAY 7)		DATE	: 08	3/18/2010	
AGAR PLATES-FORTIF COMMERCIAL	IED	DAY 7 DAY 14 DAY 21	+ + +	000	+ (O) + (O) + (O)	08/25/2010 09/01/2010 09/08/2010
AGAR PLATES-MODIFI HAYFLICK	ED	DAY 7 DAY 14 DAY 21	+ + +	000	+ (O) + (O) + (O)	08/25/2010 09/01/2010 09/08/2010
AGAR PLATES-HEART INFUSION		DAY 7 DAY 14 DAY 21	+ + +	000	+ () + () + ()	08/25/2010 09/01/2010 09/08/2010

RESULTS: No detectable mycoplasmal contamination

9/8/10

Date



Page 2 of 2

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an in vitro cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both borch and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and microaerophillically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Issuance of the final report with signature of the Laboratory Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.

BIONIQUE® TESTING LABORATORIES, INC.

Diplote Testing Laboratories Mycoplasma Testing Services

Title:DEffective Date:3/	OCF3008A D NA FLUOROCHROME A S /24/10 07	SSAY RESULTS				
		ROCHROME ocedures 3008, 3	ASSAY RESUL 3009, 3011	TS		
Sample ID # <u>62093</u>	<u>M-250</u>	Date Rec'd:	<u>08/10/2010</u>	P.O. #		2
Indicator Cells Inoculat	ted: Date/Initials:	8 12 10	/ K6			
Fixation:	Date/Initials:	8/16/10	_/K6			
Staining:	Date/Initials:	81610	/ K6	-		
TEST/CONTROL ART WA19-WB003 - <u>WA19-WB0019</u>	39 #8841 8/16/104	Ē	5 p ⁶			
LOT# <u>NA</u>		۰. ۱.				
<u>WiCell QA</u> WiCell Research	h Institute		N	n R		
			Phone: Fax #:			
* *		10 - 2 - 20	a a Ni	с Х.,		
DNA FLUOROCH	HROME ASSAY RES	ULTS:				
X_negativ		ith staining lin l contaminatio	nited to the nu	clear region,	which indicat	tes no
POSITIVI	U .	amount of ex l contamination	tranuclear stain m.	ning which s	trongly sugges	sts
INCONCI	LUSIVE:					
			tranuclear stair n or nuclear de		nt with low -]	level
	fungal or othe	er microbial c	tranuclear stair ontaminant or l contamination	viral CPE. N		
				Geo. Sec.		

S/16/10 Son W



Report Date: August 30, 2010

Case Details:

Cell Line: WA19-WB0039 (1593) Passage #: 12 Date Completed: 8/30/2010 Cell Line Gender: Male Investigator: Wisconsin International Stem Cell Bank Specimen: hESC on Matrigel Date of Sample: 8/25/2010 Tests,Reason for: lot release Results: 46,XY Completed by CG(ASCP), on 8/30/2010 Reviewed and interpreted by PhD, FACMG, on 8/30/2010

Interpretation: No clonal abnormalities were detected at the stated band level of resolution.

			annorth Artenes Artenes	Cell: S01-01 Slide: 2-4 Slide Type: Karyotyping
Course Carperta Strates announce			11 12 12 13 14 15 15 16 17 18 18	# of Cells Counted: 20 # of Cells Karyotyped: 4 # of Cells Analyzed: 8
19	20	€ 18 € 50 21 22	x y	Band Level: 400-475

Results Transmitted by Fax / Email / Post Sent By:_____ QC Review By: _____


Date:	
Sent To:	
Results Recorded:	



Cell Line: WA-19A

Cell Lot Number: NA

Sample Number: 2119A



Comments: Structures identified include Ectoderm (2), Mesoderm (2) and Endoderm (2)

Sample(s) were assessed for the presence of differentiation into cell types characteristic of the three embryonic germ layers, which, if present in the sample(s) examined, are represented in the photographs above. The individual's signature below verifies that this report accurately reflects the pathology observed.

Pathologist (By/Date): 25Febzoll QA Review (By/Date)!

Print Date: 23-Feb-11

UWHealth

Histocompatibility/Molecular Diagnostics Laboratory

University of Wisconsin Hospital and Clinics

Date: 05/18/2010 08:50:32

To: WiCell Research Institute Cytogenetics Lab



Re: High-resolution HLA results

Patient

Name		-		HLA DNA-based typing*						
HLA / MR#				Method: PCR-SSP		Direct Sequencing			PCR-SSP	
received	Dates		A*	B*	C*	DRB1*	DRB3*	DRB4*	DRB5*	DQB1*
WICELL, 2547-HLA	DQB SSP		02:01g	07:02g	03:04g	13:02/67				
63102 /	A,B,C SSP	05/14/2010	03:01g	40:01g	07:02g	15:01				
05/14/2010	DRB Seq	05/14/2010	A*03:01g n B*07:02g n B*40:01g n C*03:04g n	nay include: A nay include: B nay include: B nay include: C	lg may include: *03:01/07/08/0 *07:02/05/06/0 *40:01/25/33/4 *03:04/32/35/3 *07:02/10/29/3	7/54/61/86/91 3/74/80 8/40	34/90/195			

\cap	
ger HLA/Molecular Diagnostics Laboratory	I Director HLA/Molecular Diagnostics Laboratory
5-12-10 0857	5/20/10
Date	Date / /

This test was developed and its performance characteristics determined by the UWHC Clinical Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. However, the FDA does not require licensure of analyte specific reagents since the laboratory is approved, under CLIA, for high complexity testing. [I:\db\tx\ttmreport.fx]



National Molecular Blood Group and Platelet Testing Laboratory 700 Spring Garden Street Philadelphia, PA 19123-3594 (215) 451-4917 1-800-GIVE LIFE www.pleasegiveblood.org

06/01/10

Date received: 05/25/10

SAMPLE: <u>DNA on 2547-ABO (ML10-0809)</u> DNA on 4644-ABO (ML10-0810) Sample date: 04/28/10 Sample date: 05/18/10

INSTITUTION: WiCell Research Institute/National Stem Cell Bank (WICELL)

HISTORY: DNA samples from cell lines.

TESTING REQUESTED: Genotype for ABO and RH

DNA TESTING PERFORMED: <u>*ABO*</u>: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) testing for nucleotide positions 261 (O^1), 467 (A^2), 703 (B), and 1096 (B and O^2). <u>*RH*</u>: PCR-multiplex analysis for *RHD* exons 4, 7, the inactivating *RHD* pseudogene and C/c genotyping. <u>*RHCE*</u>: PCR-RFLP for e/E in exon 5 (676G>C).

DNA MOLECULAR RESULTS:

	Genotype	Predicted Phenotype
2547-ABO:	ABO*AO ¹ ; RHD, RHC, RHc, RHE, RHe	Group A; RhD+, C+c+, E+e+ WAP JET MARI
4644-ABO:	ABO*AB; RHD, RHC, RHe	Group AB; RhD+, C+c-, E-e+ WA20 JCT 17 Maril

RH COMMENTS: All samples were negative for the RHD-inactivating pseudogene.


Scientific Director

Supervisor

THE MOLECULAR TEST METHODS WERE DEVELOPED, AND THEIR PERFORMANCE CHARACTERISTICS DETERMINED BY THE MOLECULAR RED CELL AND PLATELET TESTING LABORATORY AT THE AMERICAN RED CROSS PENN-JERSEY REGION. THE FDA HAS NOT REVIEWED OR APPROVED THE REAGENTS USED. THESE RESULTS ARE NOT INTENDED AS THE SOLE MEANS FOR CLINICAL DIAGNOSIS OR PATIENT MANAGEMENT DECISIONS. LIMITATIONS: The genotype may not always reflect the red cell phenotype. New mutations that inactivate gene expression or rare new variant alleles may not be identified in these assays.

Please Give Blood.

Sample ID: 2547	Cell lot #: New Derivation	Characterization time point: N/A
Cell Line: WA19 TeSR	Report prepared by: JB,MW on:	Report reviewed by: JKT
Passage: p8	Date cells received: $5-12-2010 = Day 0$	Report reviewed on: 23Sep10




Regression Analysis: natural log of cell number versus Time(hours)	
The regression equation is natural log of cell number = 10.2 + 0.0286 Time(hours) Predictor Coef SE Coef T P Constant 10.1835 0.1893 53.79 0.000 Time(hours) 0.028600 0.002406 11.89 0.000	Slope ± 95% C.I. 0.028 ± 0.0049 Doubling Time ± 95% C.I.
S = 0.455252 R-Sq = 83.5% R-Sq(adj) = 82.9% Analysis of Variance	25.8 hours ± 4.6 hours
Source DF SS MS F P Regression 1 29.281 29.281 141.28 0.000 Residual Error 28 5.803 0.207 0.207 Total 29 35.084 0.001 0.001	21.2 hours – 30.4 hours

Characterization Report- Growth Characteristics

Version B Edition 01

Sample ID: 2547	Cell lot #: New Derivation	Characterization time point: N/A	
Cell Line: WA19 TeSR	Report prepared by: JB,MW on:	Report reviewed by: JKT	
Passage: p8	Date cells received: $5-12-2010 = Day 0$	Report reviewed on: 23Sep10	



Print Date: 18-Mar-11


Characterization Report- Growth Characteristics


Sample ID: 2547	Cell lot #: New Derivation	Characterization time point: N/A	
Cell Line: WA19 TeSR	Report prepared by: JB,MW on:	Report reviewed by: JKT	
Passage: p8	Date cells received: $5-12-2010 = Day 0$	Report reviewed on: 23Sep10	



Procedures performed: SOP-CH-101 SOP-CH-102 SOP-CH-103 SOP-CH-105 Cell Line: WA19 TeSR/MG Passage 8 Sample ID: 2547-FAC **Date of:** (*mm/dd/yy*) acquisition: 05/19/10 file creation: 05/19/10 file submission: 06/25/10

	SSEA4 -	SSEA4 +	SSEA4 +	SSEA4 -	ALL	ALL
antigen2:	<u>antigen2 +</u>	<u>antigen2 +</u>	<u>antigen2 -</u>	<u>antigen2 -</u>	SSEA4 +	<u>antigen2 +</u>
SSEA3	0.22	98.90	0.88	0.02	99.78	99.12
TRA1-60	0.02	96.90	3.04	0.07	99.94	96.92
TRA1-81	0.04	96.50	3.42	0.06	99.92	96.54
Oct-4	0.47	95.00	4.29	0.20	99.29	95.47
SSEA1	0.00	1.04	97.50	1.47	98.54	1.04







WiCell Cytogenetics Report: 003471 WISC2717

Report Date: 6/3/2011 Date of Sample: 7/28/2010 Investigator: Reason for Testing: WB testing Specimen: hESC on Matrigel, TeSR Karyotype Results: 46,XY

Test: WA19-WB0013-p8 (Male) Reference: WA09-MCB-01-E.3-p19(2) (Female) Project: 221 Funding: 000 CGH Accession #: 000384 GEO Accession #:

Microarray Results:	⊠ arr(1-22)x2,(XY)x1 – Male	☐ Consistent with a Balanced Karyotype (Karyotype Unavailable)
Consistant with the	Treencistent with the	Additional Eindings

oxtimes Consistent with the Karyotype Results

Inconsistent with the Karyotype Results 📙 Additional Findings

Interpretation:

CNV gains/losses

- There were 33 copy number gains and losses identified, including 2 pseudoautosomal regions and 12 copy number changes due to the reference DNA.
- Select CNVs are detailed in the table below.
- There is a >1Mb gain at 10q11.22. This CNV is likely cell line specific, is in a region of known copy number variation, and likely a benign finding.

Chr	Band (Genomic Position)	Width	Aberration Type	Classification	Genes
				Uncertain Significance –	
*3	arr 3p14.1(65,158,767-65,209,465)x3	50,697	Gain	Likely Benign	
7	arr 7q35(143,378,738-143,712,417)x3	333,679	Gain	Uncertain Significance – Likely Benign	ARHGEF5, FLJ43692, OR2A1, OR2A12, OR2A14, OR2A2, OR2A25, OR2A42, OR2A5, OR2A7
				Uncertain Significance –	
8	arr 8q21.12(78,749,603-79,151,939)x1	402,336	Loss	Likely Benign	
				Uncertain Significance –	
10	arr 10p11.21(37,490,459-37,524,112)x3	33,653	Gain	Likely Benign	ANKRD30A
10	arr 10q11.22(46,341,693-47,416,938)x3	1,075,244	Gain	Uncertain Significance – Likely Benign	ANXA8, ANXA8L1, ANXA8L2, FAM21B, GPRIN2, PPYR1, SYT15
10	arr 10q11.22(47,746,246-47,878,150)x3	131,904	Gain	Uncertain Significance – Likely Benign	ANXA8, ANXA8L1
14	arr 14q21.2q21.3(43,017,761-43,361,686)x3	343,925	Gain	Uncertain Significance – Likely Benign	
16	arr 16p13.3(2,553,293-2,673,748)x3	120,454	Gain	Uncertain Significance – Likely Benign	KCTD5, PDPK1
17	arr 17q21.31(41,586,902-41,720,893)x1	133,991	Loss	Uncertain Significance – Likely Benign	KIAA1267, LRRC37A
17	arr 17q21.31q21.32(41,788,253-42,121,257)x3	333,003	Gain	Uncertain Significance – Likely Benign	ARL17, ARL17P1, LRRC37A2, NSF
22	arr 22q11.21(18,802,736-18,961,059)x3	158,323	Gain	Uncertain Significance – Likely Benign	RIMBP3
х	arr Xq28(153,064,834-153,165,618)x1	100,784	Loss	Uncertain Significance – Likely Benign	OPN1LW, OPN1MW, OPN1MW2, TEX28

Select differentially expressed genes are in bold and underlined; classifications are based on ACMG draft guidelines

*Aberration marked manually and included in report

Notes:

- Karyotype Information no clonal abnormalities were detected at the stated band level of resolution
- Published CNVs (3) Chin et al: arr 9q34.3(137,927,276-138,466,140)x1; Narva et al: arr 10q11.22(46,341,693-47,416,938)x3

References: Werbowetski-Ogilvie, T, Bosse, M, Stewart, M, et al. (2008). Characterization of human embryonic stem cells with features of neoplastic progression. Nature Biotechnology 27, 91-97; Wu, H, Kim, K, Mehta, K, et al. (2008). Copy number variant analysis of human embryonic stem cells. Stem Cells 26, 1484-1489; Chin, MH, Mason, M, Xie, W, et al. (2009). Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123; Närvä, E, Autio R, Rahkonen N, et al. (2010). High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nature Biotechnology 28, 371-377

Recommendations: For relevant findings, confirmation and localization is recommended. Contact <u>cytogenetics@wicell.org</u> to request further testing.

Results Completed By:	MS, CG(ASCP)
Reviewed and Interpreted By:	, PhD, FACMG

aCGH Specifications:

- Platform: NimbleGen 12x135K array (HG18 WG CGH v3.1 HX12)
- Relative copy number is determined by competitive differential hybridization of labeled genomic DNA to the 135,000 oligonucleotide whole genome tiling array
- Probe length = 60mer, spanning non-repetitive regions of the human genome
- Median probe spacing = 21,500
- Analysis software: NimbleScan[™] , CGH Fusion (RBS v1.0)[™]
- Array design, genomic position, genes and chromosome banding are based on HG18.
- Analysis is based on examination of unaveraged and/or 130Kbp (10X) averaged data tracks as noted. Settings for data analysis in Infoquant include an average log-ratio threshold of 0.2, a minimum aberration length of 5 probes, p-value of 0.001. Additional analysis of this data may be performed using different ratio settings and different window averaging to enhance resolution.
- Raw data has not yet been deposited in GEO.
- Reported gains and losses are based on test to reference ratios within CGHfusion™ and the size of aberration.
- Quality assurance monitors: 1) opposite gender reference DNA ratio change in X and Y chromosomes; 2) presence of Xpter and Xq21.3 'pseudoautosomal' (PAR) imbalance; 3) presence of known reference DNA copy number changes. QA measures—PAR (2/2); Reference DNA copy number changes (12); test sample gain or loss of X and Y chromosomes consistent with the opposite gender reference sample.

Limitations: This assay will detect aneuploidy, deletions, duplications of represented loci, but will not detect balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and insertions), point mutations, loss of heterozygosity (LOH), uniparental disomy or imbalances less than 30kb in size. Copy number variants can be attributable to the test or reference samples used. Exact limits of detectable mosaicism have not been determined, but >20% mosaicism is reported to be visualized by aCGH. Actual chromosomal localization of copy number change is not determined by this assay. Other mapping procedures are required for determining chromosomal localization.

Results Transmitted by 🗌 Fax / 🗌 Email / 🗌 Post	Date:
Sent By:	Sent To:

Charles River Research Animal Diagnostic Services

251 Ballardvale Street, Wilmington, MA 01887 USA Tel: 800-338-9680 Fax: 978-658-7698

Accession #: 2010-026819

Sponsor: WiCell Research Institute			Accession #: 2010-026819					
		Diagnostic S	ummary Rep	ort				
			Received: Approved:	18 May 2010 21 May 2010, 11:54	4			
Attn:			Bill Method: Test Specimen:	Human				
Sample Set	Service (# Tested)	Profile	Assay		Tested	+	+/-	?
#1	Infectious Disease PCR (2)	All Results Negativ	ve					
				+ = Positive, -	⊦/- = Equiv	ocal, ?	= Indeter	rminate
		Service	Annrovals					

Service Approvais			
Service	Approved By*	Date	
Infectious Disease PCR		21 May 2010, 11:54	

To assure the SPF status of your research animal colonies, it is essential that you understand the sources, pathobiology, diagnosis and control of pathogens and other adventitious infectious agents that may cause research interference. We have summarized this important information in infectious agent Technical Sheets, which you can view by visiting http://www.criver.com/info/disease_sheets.

*This report has been electronically signed by laboratory personnel. The name of the individual who approved these results appears in the header of this service report. All services are performed in accordance with and subject to General Terms and Conditions of Sale found in the Charles River Laboratories-Research Models and Services catalogue and on the back of invoices.

Charles River Research Animal Diagnostic Services

251 Ballardvale Street, Wilmington, MA 01887 USA Tel: 800-338-9680 Fax: 978-658-7698

Sponsor: WiCell Research Institute

Approved by

Product: Not Indicated

Test Specimen: Human

Accession #: 2010-026819

Received: 18 May 2010

Molecular Diagnostics Infectious Disease PCR Results Report

Department Review:

21 May 2010, 11:54*

Human Comprehensive Viral PCR Panel

Sample #:	<u>1</u> WA19-WB0013	<u>2</u> WA20-WB0014
Code :	6805	8619
John Cunningham virus	-	-
BK virus	-	-
Herpesvirus type 6	-	-
Herpesvirus type 7	-	-
Herpesvirus type 8	-	-
Parvovirus B19	-	-
Epstein-Barr Virus	-	-
Hepatitis A virus	-	-
Hepatitis B virus	-	-
Hepatitis C virus	-	-
HPV-16	-	-
HPV-18	-	-
Human T-lymphotropic virus	-	-
Human cytomegalovirus	-	-
HIV-1	-	-
HIV-2	-	-
Adeno-associated virus	-	-
Human Foamy Virus	-	-
LCMV PCR	-	-
Hantavirus Hantaan PCR	-	-
Hantavirus Seoul PCR	-	-
Mycoplasma Genus PCR	-	-
DNA Spike	PASS	PASS
RNA Spike	PASS	PASS
NRC	PASS	PASS

Remarks: - = Negative; I = Inhibition, +/- = Equivocal; + = Positive.

Sample Suitability/Detection of PCR Inhibition:

Sample DNA or RNA is spiked with a low-copy number of a exogenous DNA or RNA template respectively. A spike template-specific PCR assay is used to test for the spike template for the purpose of determining the presence of PCR inhibitors. The RNA spike control is also used to evaluate the reverse-transcription of RNA. Amplification of spike template indicates that there is no detectable inhibition and the assay is valid.

NRC:

The nucleic acid recovery control (NRC) is used to evaluate the recovery of DNA/RNA from the nucleic acid isolation process. The test article is spiked with a low-copy number of DNA/RNA template prior to nucleic acid isolation. A template-specific PCR assay is used to detect the DNA/RNA spike.

*This report has been electronically signed by laboratory personnel. The name of the individual who approved these results appears in the header of this service report.